695 related articles for article (PubMed ID: 16710025)
1. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
[TBL] [Abstract][Full Text] [Related]
2. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
Johnston RL; Lutzky J; Chodhry A; Barkin JS
Dig Dis Sci; 2009 Nov; 54(11):2538-40. PubMed ID: 19104936
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
Yang JC; Hughes M; Kammula U; Royal R; Sherry RM; Topalian SL; Suri KB; Levy C; Allen T; Mavroukakis S; Lowy I; White DE; Rosenberg SA
J Immunother; 2007; 30(8):825-30. PubMed ID: 18049334
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
Blansfield JA; Beck KE; Tran K; Yang JC; Hughes MS; Kammula US; Royal RE; Topalian SL; Haworth LR; Levy C; Rosenberg SA; Sherry RM
J Immunother; 2005; 28(6):593-8. PubMed ID: 16224277
[TBL] [Abstract][Full Text] [Related]
7. The role of the CTLA4 blockade in the treatment of malignant melanoma.
Cranmer LD; Hersh E
Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
[TBL] [Abstract][Full Text] [Related]
8. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
Marthey L; Mateus C; Mussini C; Nachury M; Nancey S; Grange F; Zallot C; Peyrin-Biroulet L; Rahier JF; Bourdier de Beauregard M; Mortier L; Coutzac C; Soularue E; Lanoy E; Kapel N; Planchard D; Chaput N; Robert C; Carbonnel F
J Crohns Colitis; 2016 Apr; 10(4):395-401. PubMed ID: 26783344
[TBL] [Abstract][Full Text] [Related]
10. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
11. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
15. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
Small EJ; Tchekmedyian NS; Rini BI; Fong L; Lowy I; Allison JP
Clin Cancer Res; 2007 Mar; 13(6):1810-5. PubMed ID: 17363537
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; CalabrĂ² L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
17. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
Lens M; Ferrucci PF; Testori A
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):105-13. PubMed ID: 18537753
[TBL] [Abstract][Full Text] [Related]
18. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
Pintova S; Sidhu H; Friedlander PA; Holcombe RF
Melanoma Res; 2013 Dec; 23(6):498-501. PubMed ID: 24113862
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
Bhatia S; Huber BR; Upton MP; Thompson JA
J Immunother; 2009; 32(2):203-5. PubMed ID: 19238020
[TBL] [Abstract][Full Text] [Related]
20. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.
Movva S; Verschraegen C
Expert Opin Biol Ther; 2009 Feb; 9(2):231-41. PubMed ID: 19236253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]